Cantitate/Preț
Produs

Emerging Trends in Immunomodulatory Nanomaterials Toward Cancer Therapy: Synthesis Lectures on Biomedical Engineering

Autor Anubhab Mukherjee, Vijay Sagar Madamsetty
en Limba Engleză Paperback – 6 apr 2021
Recently, immunomodulatory nanomaterials have gained immense attention due to their involvement in the modulation of the body’s immune response to cancer therapy. This book highlights various immunomodulatory nanomaterials (including organic, polymer, inorganic, liposomes, viral, and protein nanoparticles) and their role in cancer therapy. Additionally, the mechanism of immunomodulation is reviewed in detail. Finally, the challenges of these therapies and their future outlook are discussed. We believe this book will be helpful to a broad community including students, researchers, educators, and industrialists.
Citește tot Restrânge

Din seria Synthesis Lectures on Biomedical Engineering

Preț: 37073 lei

Nou

Puncte Express: 556

Preț estimativ în valută:
7094 7450$ 5880£

Carte tipărită la comandă

Livrare economică 17-31 ianuarie 25

Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783031005411
ISBN-10: 3031005414
Pagini: 84
Ilustrații: XIV, 84 p.
Dimensiuni: 191 x 235 mm
Greutate: 0.19 kg
Editura: Springer International Publishing
Colecția Springer
Seria Synthesis Lectures on Biomedical Engineering

Locul publicării:Cham, Switzerland

Cuprins

Introduction.- Immune Response and Its Role in Cancer.- Immunomodulation and Various Strategies Effecting Immune Response.- Immunomodulatory Organic and Polymer Nanomedicine in Cancer Therapy.- Immunomodulatory Liposomes in Cancer Therapy.- Immunomodulatory Protein Nanoparticles in Cancer Therapy ' Immunomodulatory Viral Nanoparticles in Cancer Therapy.- Authors' Biographies.

Notă biografică

Dr. Anubhab Mukherjee completed his Ph.D. from the CSIR-Indian Institute of Chemical Technology, Hyderabad, India, having been skilled with RNAi, liposomal drug delivery in cancer, preclinical cell, and animal studies. He pursued post-doctoral research at the College of Pharmacy, Health Science Center, Texas A&M University, and was involved in another postdoctoral research at Department of Translational Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, Santa Monica, California. In 2015, he worked at the Harvard-MIT Health Sciences and Technology as a visiting scientist. He has substantial experience in nanotechnology-based formulation development and successfully worked for various Indian organizations to develop pharmaceuticals and nutraceutical formulations. He is an inventor of many U.S. patents and an author of many peer-reviewed articles published in various international journals of repute. Dr. Mukherjee is currently serving as Principal Scientist, R&D at EspererOnco Nutrition (EON) Pvt. Ltd. and heads the Hyderabad R&D center of the organization.
Dr. Vijay Sagar Madamsetty received his Ph.D. in chemical science from the Academy of Scientific and Innovative Research (AcSIR), India. He has had a passion for developing cutting-edge research on nanomedicine for about ten years, starting from the Council of Scientific and Industrial Research-Indian Institute of Chemical Technology (CSIR-IICT) and continuing to the present as a senior postdoctoral fellow at the Mayo Clinic Florida in the Department of Biochemistry and Molecular Biology. He is currently developing multiple drugs/genes encapsulating targeted nanoformulations and their preclinical evaluation in several dis ease animal models. Dr. Madamsetty’s long-term research inter ests involve understanding key signaling pathways and how alterations in gene expression contribute to human diseases, leading to developing effective targeted nanomedicine. He is also an active reviewer and editorialboard member of several international journals.
Dr. Sudip Mukherjee completed his Ph.D. from the CSIR-Indian Institute of Chemical Technology, Hyderabad, India. Dr. Mukherjee is currently working as a Postdoctoral Research Associate at Rice University. His research is involved in the development of advanced nanomaterials for drug/gene delivery in cancer theranostics, immunomodulatory applications, and angiogenesis. He has published a total of ~50 research articles/patents. He serves as International Advisory Board Member for “Materials Research Express,” IOP Sciences. He is a member (MRSC) of RSC, UK. He serves as reviewer for several international journals such as ChemComm, Journal of Materials Chemistry A, Journal of Materials Chemistry B, Journal of Biomedical Nanotechnology, RSC Advances, and IOP Nanotechnology, Biofabrication.